NCT07634536尚未招募2 期
Automated Total Marrow and Lymphoid Irradiation for Allogeneic Hematopoietic Cell Transplant
适应症
试验速览
- 阶段
- 2 期
- 状态
- 尚未招募
- 入组人数
- 30
- 试验地点
- 1
研究概览
简要总结
Intensive conditioning regimens used in allogeneic hematopoietic cell transplant (HCT) help to eliminate hematologic tumors and reduce the risk of relapse, but are also characterized by high toxicity. Total marrow and lymphoid irradiation (TMLI) is a specialized radiation technique that specifically targets marrow and lymphoid tissue to maximize antitumor efficacy while reducing off target toxicity. Despite these benefits, TMLI is technically challenging and time consuming. The radiation oncology team at Stanford has developed an automated TMLI platform to overcome these challenges. In this phase II trial, automation will be incorporated into a previously validated conditioning regimen of fludarabine/cyclophosphamide/TMLI HCT with post-transplant cyclophosphamide (PTCy) for graft-versus-host disease (GVHD) prophylaxis to confirm the feasibility and safety of automation in patients receiving allogeneic HCT for high-risk myeloid malignancies.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 70 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •for 20 Gy Arm (Cohort A)
- •Age, Performance Status, and Graft Criteria require all of the following bullet points:
- •Age 18 to 60 years (inclusive)
- •HCT Co-Morbidity score (HCT-CI) < 5 (http://www.qxmd.com/calculate-online/hematology/hct-ci)(31)
- •Adequate performance status is defined as Karnofsky score ≥ 70%
- •Patients must be receiving an allogeneic peripheral blood stem cell graft
- •Patients and selected donor must be HLA typed at high resolution using DNA based typing at the following HLA-loci: HLA-A, -B, -C and DRB
- •Donors may be an 8/8 matched sibling donor, 8/8 matched unrelated donor, haploidentical related donor, or 7/8 mismatched unrelated donor.
- •Eligible Diseases (Any one of the following)
- •Acute Myeloid Leukemia (AML) Must have at least one of the following characteristics:
- •Blasts >5% in the peripheral blood and/or bone marrow after >2 prior lines of AML directed therapy, present during the trial screening window
- •Adverse plus risk by AlloHCT Refined ELN Criteria: defined as having complex cytogenetics, TP53 mutation, or MECOM rearrangement confirmed at any time point.(32)
- •Myelodysplastic syndrome Must have at least one of the following characteristics at the time of conditioning:
- •Blasts >10% in the peripheral blood and/or bone marrow after >1 prior line of therapy.
- •TP53 mutation confirmed at any time point
- •Myeloproliferative neoplasms (MPN) or MDS/MPN overlap. Must have at least one of the following characteristics:
- •Blasts >10% in the peripheral blood and/or bone marrow during the trial screening window
- •TP53 mutation confirmed at any time point
- •Adequate organ function is defined as all of the following:
- •Cardiac: Absence of decompensated congestive heart failure, or uncontrolled arrhythmia and left ventricular ejection fraction > 45% confirmed by MUGA or echocardiography Pulmonary: DLCO, FEV1, FVC > 50% predicted, and absence of O2 requirements. Liver: Transaminases < 3 x upper limit of normal (ULN) and total bilirubin ≤ 2 mg/dL except for patients with Gilbert's syndrome or hemolysis (as indicated by provider documentation).
- •Renal: Creatinine < 2.0 mg/dL (adults) and creatinine clearance > 40 mL/min.
- •Must be FIRST allogeneic HCT
- •Sexually active females of childbearing potential and males with partners of child-bearing potential must agree to use adequate birth control during study treatment.
- •Voluntary written consent
- •Inclusion Criteria for 12 Gy Arm (Cohort B)
- •Age, Performance Status, and Graft Criteria require all of the following bullet points:
- •Age 18 to 70 years (inclusive) Adequate performance status is defined as Karnofsky score ≥ 70% Patients must be receiving an allogeneic peripheral blood stem cell graft Patients and selected donor must be HLA typed at high resolution using DNA based typing at the following HLA-loci: HLA-A, -B, -C and DRB
- •Donors may be an 8/8 matched sibling donor, 8/8 matched unrelated donor, haploidentical related donor, or 7/8 mismatched unrelated donor.
- •Eligible Diseases (Any of the following) Acute Myeloid Leukemia (AML) Myelodysplastic syndrome Myeloproliferative neoplasm MDS/MPN overlap
- •Must have relapse after prior allo HCT
- •Adequate organ function is defined as all of the following:
- •Cardiac: Absence of decompensated congestive heart failure, or uncontrolled arrhythmia and left ventricular ejection fraction > 40% confirmed by MUGA or echocardiography Pulmonary: DLCO, FEV1, FVC > 40% predicted, and absence of O2 requirements. Liver: Transaminases < 3 x upper limit of normal (ULN) and total bilirubin ≤ 2 mg/dL except for patients with Gilbert's syndrome or hemolysis (as indicated by provider documentation).
- •Renal: Creatinine < 2.0 mg/dL (adults) and creatinine clearance > 40 mL/min. Sexually active females of childbearing potential and males with partners of child-bearing potential must agree to use adequate birth control during study treatment.
- •Voluntary written consent
排除标准
- •Pregnant or breast feeding. The agents used in this study include Pregnancy Category D: known to cause harm to a fetus. Females of childbearing potential must have a negative pregnancy test prior to starting therapy.
- •Untreated active infection. Controlled or asymptomatic infections requiring continued antimicrobial therapy are permissible.
- •Active HIV infection, defined as HIV infection with detectable viral load
- •Active central nervous system malignancy
- •GVHD requiring systemic therapy including > 0.25 mg/kg prednisone (or equivalent) or other systemic therapy for GVHD (e.g., tacrolimus, sirolimus, ruxolitinib, belumosodil, ibrutinib, axatilimab).
- •Any other medical or psychological condition that is deemed serious and unsafe for clinical trial participation.
- •Exposure to prior radiation that is deemed unsafe for clinical trial participation.
研究者
研究点 (1)
Loading locations...
相似试验
招募中
1 期
Proton-Based Total Marrow Irradiation for Allogeneic Transplantation in High-Risk AML/MDSAcute Myeloid Leukemia (AML)Myelodysplastic Syndrome (MDS)/AMLProton TherapyMDS and AML Prior to Allogeneic SCTMyelodysplastic NeoplasmNCT07532824Institute of Hematology and Blood Transfusion, Czech Republic16
招募中
2 期
Allogeneic hematopoietic cell transplantation from HLA-matched donor after Flu-Mel-PTCy versus Flu-Mel-ATG reduced-intensity conditioning: a phase II randomized study from the Belgian Hematology Society (BHS)2024-518568-11-00Centre Hospitalier Universitaire De Liege, Centre Hospitalier Universitaire De Liege114
招募中
2 期
Haploidentical Donor Hematopoietic Cell Transplant for Sickle Cell DiseaseSickle Cell DiseaseNCT07616154St. Jude Children's Research Hospital45
招募中
2 期
Total Marrow and Lymphoid Irradiation in Combination With Fludarabine and Melphalan as Conditioning for Allogeneic Peripheral Blood Stem Cell Hematopoietic Cell Transplant in Older Patients With Refractory and Relapsed Acute Myeloid Leukemia and High-risk Myelodysplastic SyndromeMyelodysplastic SyndromeNCT07582172City of Hope Medical Center35
招募中
2 期
Hematopoietic Stem Cell Transplantation (HSCT) for Common Variable Immunodeficiency (CVID) and Other Autoimmune Manifestations of Primary Immune Regulatory Disorders (PIRD)Chronic Granulomatous DiseaseNCT07284641Paul Szabolcs25